Protofibril selective antibodies and the use thereof
AssigneeBioArctic Neuroscience AB
InventorsPär Gellerfors, Lars Lannfelt, Dag Sehlin, Frida Ekholm Pettersson, Hillevi Englund
Life of this patent
Estimating the term…
Abstract
The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (Aβ) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or mutations thereof, retaining high Fc receptor binding and low C1(C1q) binding, effective in clearance of Aβ protofibrils and with reduce risk of inflammation.
Claims25
An isolated antibody or fragment thereof being selective and having high affinity for human Aβ protofibrils, wherein the antibody or fragment in its six CDR regions comprises the following consensus sequences:
- VH-CDR1
- SFGMH
- (SEQ ID NO:
- 1);
- VH-CDR2
- YISSGSSTIYYGDTVKG
- (SEQ ID NO:
- 2);
- VH-CDR3
- EGGYYYGRSYYTMDY
- (SEQ ID NO:
- 3);
- VL-CDR1
- RSSQSIVHSNGNTYLE
- (SEQ ID NO:
- 4);
- VL-CDR2
- KVSNRFS
- (SEQ ID NO:
- 5);
- and
- VL-CDR3
- FQGSHVPPT
- (SEQ ID NO:
- 6).
An isolated antibody or fragment thereof that binds to human Aβ protofibrils, wherein the antibody or fragment comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence 158RHA in Table 27 (SEQ ID NO:158) and the light chain comprises the amino acid sequence 158RKA in Table 38 (SEQ ID NO:244).
Dependencies are inferred from the claim text.